| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Donald F Tang last filed a Form 4 in August 2025, as Director at RBOT. Donald F Tang's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Donald F Tang's trades have earned a strong insider score of 84/100 across 3 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +99.4%.
At the last filing, the largest reported position was 40,425 shares of RBOT. The RBOT filings lean toward selling, a net 4,912 shares.
Donald F Tang has 11 Form 4 filings on record from November 2021 to August 2025, across 2 companies: Director at Vicarious Surgical (RBOT), 2021–2025; Director at Senti Biosciences (SNTI), 2024–2025.
The 14 reported transactions were 5 stock awards, 4 option or other derivative awards, 3 open-market sales and 2 other transactions.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $32K.
The largest open-market sale was 2,753 shares of RBOT at an average $6.70 on August 26, 2025, about $18K. Twelve months later RBOT was down 99%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from August 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.